Oppenheimer Maintains Outperform on Tandem Diabetes Care, Raises Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on Tandem Diabetes Care (NASDAQ:TNDM) and raises the price target from $47 to $58.
June 10, 2024 | 11:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer's analyst Steven Lichtman has maintained an Outperform rating on Tandem Diabetes Care and increased the price target from $47 to $58, indicating a positive outlook for the stock.
The increase in price target from $47 to $58 by a reputable analyst suggests a strong positive outlook for Tandem Diabetes Care. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100